{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:19Z","timestamp":1783908499563,"version":"3.55.0"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2019-0016_s_006_w2aab3b7b3b1b6b1aab1c18b1Aa\">\n                    <jats:title id=\"d2965566e72011_w2aab3b7b3b1b6b1aab1c18b1aAa\">Background<\/jats:title>\n                    <jats:p>\n                      Malignant mesothelioma (MM) is a rare aggressive tumour of mesothelium caused by asbestos exposure. It has been suggested that the genetic variability of proteins involved in DNA repair mechanisms affects the risk of MM. This study investigated the influence of functional polymorphisms in\n                      <jats:italic>ERCC1<\/jats:italic>\n                      and\n                      <jats:italic>XRCC1<\/jats:italic>\n                      genes, the interactions between these polymorphisms as well as the interactions between these polymorphisms and asbestos exposure on MM risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2019-0016_s_007_w2aab3b7b3b1b6b1aab1c18b2Aa\">\n                    <jats:title id=\"d2965566e72025_w2aab3b7b3b1b6b1aab1c18b2aAa\">Patients and methods<\/jats:title>\n                    <jats:p>\n                      In total, 237 cases with MM and 193 controls with no asbestos-related disease were genotyped for\n                      <jats:italic>ERCC1<\/jats:italic>\n                      and\n                      <jats:italic>XRCC1<\/jats:italic>\n                      polymorphisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2019-0016_s_008_w2aab3b7b3b1b6b1aab1c18b3Aa\">\n                    <jats:title id=\"d2965566e72039_w2aab3b7b3b1b6b1aab1c18b3aAa\">Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ERCC1<\/jats:italic>\n                      rs3212986 polymorphism was significantly associated with a decreased risk of MM (odds ratio [OR] = 0.61; 95% confidence interval [CI] = 0.41\u20130.91; p = 0.014). No associations were observed between other genetic polymorphisms and MM risk. Interactions between polymorphisms did not significantly influence MM risk. Interaction between\n                      <jats:italic>ERCC1<\/jats:italic>\n                      rs11615 and asbestos exposure significantly influenced MM risk (OR = 3.61; 95% CI = 1.12\u201311.66; p = 0.032). Carriers of polymorphic\n                      <jats:italic>ERCC1<\/jats:italic>\n                      rs11615 allele who were exposed to low level of asbestos had a decreased risk of MM (OR = 0.40; 95% CI = 0.19\u20130.84; p = 0.016). Interactions between other polymorphisms and asbestos exposure did not significantly influence MM risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2019-0016_s_009_w2aab3b7b3b1b6b1aab1c18b4Aa\">\n                    <jats:title id=\"d2965566e72055_w2aab3b7b3b1b6b1aab1c18b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that the genetic variability of DNA repair mechanisms could contribute to the risk of developing MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2019-0016","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T05:11:10Z","timestamp":1553058670000},"page":"206-212","source":"Crossref","is-referenced-by-count":7,"title":["The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma"],"prefix":"10.2478","volume":"53","author":[{"given":"Kristina","family":"Levpuscek","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Goricar","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljem","family":"Kovac","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Dolzan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Franko","sequence":"additional","affiliation":[{"name":"Clinical Institute of Occupational Medicine, University Medical Center Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"2026071214254945909_j_raon-2019-0016_ref_001_w2aab3b7b3b1b6b1ab1b4b1Aa","doi-asserted-by":"crossref","unstructured":"Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012; 227: 44-58. doi: 10.1002\/jcp.22724","DOI":"10.1002\/jcp.22724"},{"key":"2026071214254945909_j_raon-2019-0016_ref_002_w2aab3b7b3b1b6b1ab1b4b2Aa","doi-asserted-by":"crossref","unstructured":"Linton A, Vardy J, Clarke S, van Zandwijk N. The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol 2012; 84: 200-12. doi: 10.1016\/j.critrevonc.2012.03.001","DOI":"10.1016\/j.critrevonc.2012.03.001"},{"key":"2026071214254945909_j_raon-2019-0016_ref_003_w2aab3b7b3b1b6b1ab1b4b3Aa","doi-asserted-by":"crossref","unstructured":"Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-11. doi: 10.2478\/raon-2018-0004","DOI":"10.2478\/raon-2018-0004"},{"key":"2026071214254945909_j_raon-2019-0016_ref_004_w2aab3b7b3b1b6b1ab1b4b4Aa","doi-asserted-by":"crossref","unstructured":"Remon J, Lianes P, Martinez S, Velasco M, Querol R, Zanui M. Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev 2013; 39: 584-91. doi: 10.1016\/j.ctrv.2012.12.005","DOI":"10.1016\/j.ctrv.2012.12.005"},{"key":"2026071214254945909_j_raon-2019-0016_ref_005_w2aab3b7b3b1b6b1ab1b4b5Aa","doi-asserted-by":"crossref","unstructured":"Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelinrelated peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31. doi: 10.3233\/DMA-2011-0866","DOI":"10.1155\/2012\/430689"},{"key":"2026071214254945909_j_raon-2019-0016_ref_006_w2aab3b7b3b1b6b1ab1b4b6Aa","doi-asserted-by":"crossref","unstructured":"Weiner SJ, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Cancer Res Clin Oncol 2009; 135: 15-27. doi: 10.1007\/s00432-008-0444-9","DOI":"10.1007\/s00432-008-0444-9"},{"key":"2026071214254945909_j_raon-2019-0016_ref_007_w2aab3b7b3b1b6b1ab1b4b7Aa","doi-asserted-by":"crossref","unstructured":"Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004; 14: 469-77, viii. doi: 10.1016\/j. thorsurg.2004.06.011","DOI":"10.1016\/j.thorsurg.2004.06.011"},{"key":"2026071214254945909_j_raon-2019-0016_ref_008_w2aab3b7b3b1b6b1ab1b4b8Aa","doi-asserted-by":"crossref","unstructured":"Sen D. Working with asbestos and the possible health risks. Occup Med (Lond) 2015; 65: 6-14. doi: 10.1093\/occmed\/kqu175","DOI":"10.1093\/occmed\/kqu175"},{"key":"2026071214254945909_j_raon-2019-0016_ref_009_w2aab3b7b3b1b6b1ab1b4b9Aa","doi-asserted-by":"crossref","unstructured":"Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007; 45: 379-87. doi: 10.2486\/ indhealth.45.379","DOI":"10.2486\/indhealth.45.379"},{"key":"2026071214254945909_j_raon-2019-0016_ref_010_w2aab3b7b3b1b6b1ab1b4c10Aa","doi-asserted-by":"crossref","unstructured":"Case BW, Abraham JL, Meeker G, Pooley FD, Pinkerton KE. Applying definitions of \u201casbestos\u201d to environmental and \u201clow-dose\u201d exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev 2011; 14: 3-39. doi: 10.1080\/10937404.2011.556045","DOI":"10.1080\/10937404.2011.556045"},{"key":"2026071214254945909_j_raon-2019-0016_ref_011_w2aab3b7b3b1b6b1ab1b4c11Aa","doi-asserted-by":"crossref","unstructured":"Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci 2009; 71: 1-10. doi: 10.1265\/jjh.66.562","DOI":"10.1265\/jjh.66.562"},{"key":"2026071214254945909_j_raon-2019-0016_ref_012_w2aab3b7b3b1b6b1ab1b4c12Aa","doi-asserted-by":"crossref","unstructured":"Upadhyay D, Kamp DW. Asbestos-induced pulmonary toxicity: role of DNA damage and apoptosis. Exp Biol Med (Maywood) 2003; 228: 650-9. doi: 10.1177\/153537020322800602","DOI":"10.1177\/153537020322800602"},{"key":"2026071214254945909_j_raon-2019-0016_ref_013_w2aab3b7b3b1b6b1ab1b4c13Aa","doi-asserted-by":"crossref","unstructured":"Manning CB, Vallyathan V, Mossman BT. Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol 2002; 2: 191-200. doi: 10.1016\/S1567-5769(01)00172-2","DOI":"10.1016\/S1567-5769(01)00172-2"},{"key":"2026071214254945909_j_raon-2019-0016_ref_014_w2aab3b7b3b1b6b1ab1b4c14Aa","doi-asserted-by":"crossref","unstructured":"Dianzani I, Gibello L, Biava A, Giordano M, Bertolotti M, Betti M, et al. Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat Res 2006; 599: 124-34. doi: 10.1016\/j.mrfmmm.2006.02.005","DOI":"10.1016\/j.mrfmmm.2006.02.005"},{"key":"2026071214254945909_j_raon-2019-0016_ref_015_w2aab3b7b3b1b6b1ab1b4c15Aa","doi-asserted-by":"crossref","unstructured":"Betti M, Ferrante D, Padoan M, Guarrera S, Giordano M, Aspesi A, et al. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study. Mutat Res 2011; 708: 11-20. doi: 10.1016\/j.mrfmmm.2011.01.001","DOI":"10.1016\/j.mrfmmm.2011.01.001"},{"key":"2026071214254945909_j_raon-2019-0016_ref_016_w2aab3b7b3b1b6b1ab1b4c16Aa","doi-asserted-by":"crossref","unstructured":"Spivak G. Nucleotide excision repair in humans. DNA Repair (Amst) 2015; 36: 13-8. doi: 10.1016\/j.dnarep.2015.09.003","DOI":"10.1016\/j.dnarep.2015.09.003"},{"key":"2026071214254945909_j_raon-2019-0016_ref_017_w2aab3b7b3b1b6b1ab1b4c17Aa","doi-asserted-by":"crossref","unstructured":"Zhang L, Wang J, Xu L, Zhou J, Guan X, Jiang F, et al. Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis. Mutagenesis 2012; 27: 67-76. doi: 10.1093\/mutage\/ger062","DOI":"10.1093\/mutage\/ger062"},{"key":"2026071214254945909_j_raon-2019-0016_ref_018_w2aab3b7b3b1b6b1ab1b4c18Aa","doi-asserted-by":"crossref","unstructured":"Zhao Z, Zhang A, Zhao Y, Xiang J, Yu D, Liang Z, et al. The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility. Biosci Rep 2018; 38(3): BSR20180114. doi: 10.1042\/BSR20180114","DOI":"10.1042\/BSR20180114"},{"key":"2026071214254945909_j_raon-2019-0016_ref_019_w2aab3b7b3b1b6b1ab1b4c19Aa","doi-asserted-by":"crossref","unstructured":"Manandhar M, Boulware KS, Wood RD. The ERCC1 and ERCC4 (XPF) genes and gene products. Gene 2015; 569: 153-61. doi: 10.1016\/j. gene.2015.06.026","DOI":"10.1016\/j.gene.2015.06.026"},{"key":"2026071214254945909_j_raon-2019-0016_ref_020_w2aab3b7b3b1b6b1ab1b4c20Aa","doi-asserted-by":"crossref","unstructured":"Ding YW, Gao X, Ye DX, Liu W, Wu L, Sun HY. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies. Clin Transl Oncol 2015; 17: 710-9. doi: 10.1007\/s12094-015-1298-7","DOI":"10.1007\/s12094-015-1298-7"},{"key":"2026071214254945909_j_raon-2019-0016_ref_021_w2aab3b7b3b1b6b1ab1b4c21Aa","doi-asserted-by":"crossref","unstructured":"Li B, Shi X, Yuan Y, Peng M, Jin H, Qin D. ERCC1 rs11615 polymorphism increases susceptibility to breast cancer: a meta-analysis of 4547 individuals. Biosci Rep 2018; 38(3): BSR20180440. doi: 10.1042\/BSR20180440","DOI":"10.1042\/BSR20180440"},{"key":"2026071214254945909_j_raon-2019-0016_ref_022_w2aab3b7b3b1b6b1ab1b4c22Aa","doi-asserted-by":"crossref","unstructured":"Chen J, Sun N, Hu G, Chen X, Jiang J, Wu H, et al. Association of ERCC1 polymorphisms with the risk of colorectal cancer: a meta-analysis. Crit Rev Eukaryot Gene Expr 2017; 27(3): 267-75. doi: 10.1615\/ CritRevEukaryotGeneExpr.2017019713","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019713"},{"key":"2026071214254945909_j_raon-2019-0016_ref_023_w2aab3b7b3b1b6b1ab1b4c23Aa","doi-asserted-by":"crossref","unstructured":"De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, et al. Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World J Gastroenterol 2017; 23: 6674-84. doi: 10.3748\/wjg.v23.i36.6674","DOI":"10.3748\/wjg.v23.i36.6674"},{"key":"2026071214254945909_j_raon-2019-0016_ref_024_w2aab3b7b3b1b6b1ab1b4c24Aa","doi-asserted-by":"crossref","unstructured":"London RE. The structural basis of XRCC1-mediated DNA repair. DNA repair. 2015; 30: 90-103. doi: 10.1016\/j.dnarep.2015.02.005","DOI":"10.1016\/j.dnarep.2015.02.005"},{"key":"2026071214254945909_j_raon-2019-0016_ref_025_w2aab3b7b3b1b6b1ab1b4c25Aa","doi-asserted-by":"crossref","unstructured":"Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2003; 2: 901-8. doi: 10.1016\/S1568-7864(03)00085-5","DOI":"10.1016\/S1568-7864(03)00085-5"},{"key":"2026071214254945909_j_raon-2019-0016_ref_026_w2aab3b7b3b1b6b1ab1b4c26Aa","doi-asserted-by":"crossref","unstructured":"Srivastava A, Srivastava K, Pandey SN, Choudhuri G, Mittal B. Singlenucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population. Ann Surg Oncol 2009; 16: 1695-703. doi: 10.1245\/s10434-009-0354-3","DOI":"10.1245\/s10434-009-0354-3"},{"key":"2026071214254945909_j_raon-2019-0016_ref_027_w2aab3b7b3b1b6b1ab1b4c27Aa","unstructured":"Jafari Nedooshan J, Forat Yazdi M, Neamatzadeh H, Zare Shehneh M, Kargar S, Seddighi N. Genetic association of XRCC1 gene rs1799782, rs25487 and rs25489 polymorphisms with risk of thyroid cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2017; 18: 263-70. doi: 10.22034\/ APJCP.2017.18.1.263"},{"key":"2026071214254945909_j_raon-2019-0016_ref_028_w2aab3b7b3b1b6b1ab1b4c28Aa","doi-asserted-by":"crossref","unstructured":"Zhu DQ, Zou Q, Hu CH, Su JL, Zhou GH, Liu P. XRCC1 genetic polymorphism acts a potential biomarker for lung cancer. Tumour Biol 2015; 36: 3745-50. doi: 10.1007\/s13277-014-3014-6","DOI":"10.1007\/s13277-014-3014-6"},{"key":"2026071214254945909_j_raon-2019-0016_ref_029_w2aab3b7b3b1b6b1ab1b4c29Aa","doi-asserted-by":"crossref","unstructured":"Dodic Fikfak M, Kriebel D, Quinn MM, Eisen EA, Wegman DH. A case control study of lung cancer and exposure to chrysotile and amphibole at a slovenian asbestos-cement plant. Ann Occup Hyg 2007; 51: 261-8. doi: 10.1093\/annhyg\/mem003","DOI":"10.1093\/annhyg\/mem003"},{"key":"2026071214254945909_j_raon-2019-0016_ref_030_w2aab3b7b3b1b6b1ab1b4c30Aa","doi-asserted-by":"crossref","unstructured":"Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-71.","DOI":"10.1136\/oem.17.4.260"},{"key":"2026071214254945909_j_raon-2019-0016_ref_031_w2aab3b7b3b1b6b1ab1b4c31Aa","unstructured":"Muscat JE, Wynder EL. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res 1991; 51: 2263-7."},{"key":"2026071214254945909_j_raon-2019-0016_ref_032_w2aab3b7b3b1b6b1ab1b4c32Aa","doi-asserted-by":"crossref","unstructured":"Berry G, Newhouse ML, Antonis P. Combined effect of asbestos and smoking on mortality from lung cancer and mesothelioma in factory workers. Br J Ind Med 1985; 42: 12-8.","DOI":"10.1136\/oem.42.1.12"},{"key":"2026071214254945909_j_raon-2019-0016_ref_033_w2aab3b7b3b1b6b1ab1b4c33Aa","doi-asserted-by":"crossref","unstructured":"Lacourt A, Leveque E, Guichard E, Gilg Soit Ilg A, Sylvestre MP, Leffondre K. Dose-time-response association between occupational asbestos exposure and pleural mesothelioma. Occup Environ Med 2017; 74: 691-7. doi: 10.1136\/oemed-2016-104133","DOI":"10.1136\/oemed-2016-104133"},{"key":"2026071214254945909_j_raon-2019-0016_ref_034_w2aab3b7b3b1b6b1ab1b4c34Aa","doi-asserted-by":"crossref","unstructured":"Ulvestad B, Kjaerheim K, Martinsen JI, Damberg G, Wannag A, Mowe G, et al. Cancer incidence among workers in the asbestos-cement producing industry in Norway. Scand J Work Environ Health 2002; 28: 411-7. doi: 10.5271\/sjweh.693","DOI":"10.5271\/sjweh.693"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/53\/2\/article-p206.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2019-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:40:49Z","timestamp":1783906849000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2019-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,3,14]]},"published-print":{"date-parts":[[2019,3,14]]}},"alternative-id":["10.2478\/raon-2019-0016"],"URL":"https:\/\/doi.org\/10.2478\/raon-2019-0016","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]}}}